The effect of apple cider vinegar tablet on metabolic syndrome and insulin resistance in PCOS patients: A randomized double-blind trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150905023897N7

Enrollment

Registered

2023-12-11

Start date

2023-11-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Metabolic syndrome in PCOS patients. Condition 2: Insulin resistance in PCOS patients.

Interventions

Intervention 1: Intervention group: Treatment by Apple cider vinegar tablet 500 mg. Intervention 2: Control group: Treatment by placebo of Apple cider vinegar tablet.

Eligibility

Sex/Gender

Female

Age

15 Years to 49 Years

Inclusion criteria

Inclusion criteria: fertility age between 15-49 years Iranian women No pregnancy Have at least literacy for read and write No Mellitus Diabets according to primary FBS No chronic diseases affecting PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, thyroid dysfunction) Lack of consumption Anti lipids and Anti hypertensive and anti coagulative drugs during the last three months People are willing to participate in the study

Exclusion criteria

Exclusion criteria: People with drug side effects Individuals unwilling to continue to participate in the study failure to comply with treatment protocol

Design outcomes

Primary

Measure	Time frame
Blood level of FBS. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of Insulin. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Level of Triglyceride. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Level of total cholesterol. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of LDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of HDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of testostrone. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Weight. Timepoint: First of study and 12 weeks after intervention. Method of measurement: use of scale.;Waist to hip ratio. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of meter.;Level of systolic and diastolic blood pressure. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of mercury barometer.	—

Measure

Time frame

Blood level of FBS. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of Insulin. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Level of Triglyceride. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Level of total cholesterol. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of LDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of HDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Blood level of testostrone. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.;Weight. Timepoint: First of study and 12 weeks after intervention. Method of measurement: use of scale.;Waist to hip ratio. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of meter.;Level of systolic and diastolic blood pressure. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of mercury barometer.

—

Secondary

Measure	Time frame
Menstrual dysfunction such as: Oligomenorrhea and amenorrhea. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Patient statements.;Clinical hyperandrogenemia. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test and clinical symptom.;Ultrasound view of the ovaries. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of ultrasound.;Sexual function. Timepoint: First of study and 12 weeks after intervention. Method of measurement: FSFI questionnaire.;Quality Of life. Timepoint: First of study and 12 weeks after intervention. Method of measurement: MPCOSQ questionnaire.	—

Measure

Time frame

Menstrual dysfunction such as: Oligomenorrhea and amenorrhea. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Patient statements.;Clinical hyperandrogenemia. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test and clinical symptom.;Ultrasound view of the ovaries. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of ultrasound.;Sexual function. Timepoint: First of study and 12 weeks after intervention. Method of measurement: FSFI questionnaire.;Quality Of life. Timepoint: First of study and 12 weeks after intervention. Method of measurement: MPCOSQ questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahideh Jahanian Sadatmahalleh

Tarbiat modares University

Shahideh.jahanian@modares.ac.ir+98 21 2230 6480

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: May 31, 2026